‘Significant’ Cases of Neurological Disorder Associated with the AstraZeneca Vaccine

A UK study by University College London has confirmed “small but significant” cases of the serious Guillain-Barre syndrome (GBS), a rare neurological disorder associated with the AstraZeneca vaccine for COVID-19.

The researchers speculate that “the majority or all” of the 121 UK cases of GBS (pdf) in March to April 2021 were associated with first doses of the AstraZeneca vaccine administered in January.

“A similar pattern is not seen with the other vaccines or following a second dose of any vaccine,” said lead author Prof. Michael Lunn on May 30.

The team observed that from January to October 2021, 996 GBS cases were recorded in the national database but with an unusual spike from March to April with about 140 cases per month rather than 100.